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Abstract: AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay Screen) is versatile assay technology 
developed to measuring analytes using a homogenous protocol. This technology is an example of a bead-based proximity 
assay and was developed from a diagnostic assay technology known as LOCI (Luminescent Oxygen Channeling Assay). 
Here, singlet oxygen molecules, generated by high energy irradiation of Donor beads, travel over a constrained distance 
(approx. 200 nm) to Acceptor beads. This results in excitation of a cascading series of chemical reactions, ultimately caus-
ing generation of a chemiluminescent signal.  
In the past decade, a wide variety of applications has been reported, ranging from detection of analytes involved in cell 
signaling, including protein:protein, protein:peptide, protein:small molecule or peptide:peptide interactions. Numerous 
homogeneous HTS-optimized assays have been reported using the approach, including generation of second messengers 
(such as accumulation of cyclic AMP, cyclic GMP, inositol [1, 4, 5] trisphosphate or phosphorylated ERK) from liganded 
GPCRs or tyrosine kinase receptors, post-translational modification of proteins (such as proteolytic cleavage, phosphory-
lation, ubiquination and sumoylation) as well as protein-protein and protein-nucleic acid interactions.  
Recently, the basic AlphaScreen technology was extended in that the chemistry of the Acceptor bead was modified such 
that emitted light is more intense and spectrally defined, thereby markedly reducing interference from biological fluid ma-
trices (such as trace hemolysis in serum and plasma). In this format, referred to as AlphaLISA, it provides an alternative 
technology to classical ELISA assays and is suitable for high throughput automated fluid dispensing and detection systems.  
Collectively, AlphaScreen and AlphaLISA technologies provide a facile assay platform with which one can quantitate 
complex cellular processes using simple no-wash microtiter plate based assays. They provide the means by which large 
compound libraries can be screened in a high throughput fashion at a diverse range of therapeutically important targets, 
often not readily undertaken using other homogeneous assay technologies. This review assesses the current status of the 
technology in drug discovery, in general, and high throughput screening (HTS), in particular. 
INTRODUCTION 
  AlphaScreen is a channeling immunoassay in which the 
immune reaction coordinates two bead components into 
close proximity on a defined physical surface. At that sur-
face, one component produces a product that serves to acti-
vate a second component, thereby producing a detectable 
signal. In many aspects of drug discovery, principally high 
throughput screening (HTS), AlphaScreen has been widely 
deployed in aspects of cell signaling research, drug discov-
ery and biomarker quantification [1-5]. This is wide adoption 
results from both the simplicity of assay protocols, but also 
from the high sensitivity of the assay. These two properties, 
as well as with the fact that wash and separation are not 
used, allow a range of assays to be configured for automated 
liquid handling and detection instrumentation frequently 
used in HTS.  
  The technology employs oxygen channeling chemistry 
developed initially as a diagnostic detection assay platform - 
LOCI [6-7]. The approach exploits the short diffusional   
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distance of singlet oxygen to initiate a chemiluminescent 
reaction in the proximity of chemical generation. In contrast 
to other methods based upon light scattering, the method is 
insensitive to interference by particles or other substances 
present in biological sample matrices. The assay format 
comprises two discrete ligand - or receptor - coated polysty-
rene beads, designated as “Donor” and “Acceptor” beads, 
which form pairs in the presence of analyte. The pairs must 
be within about 200 nm (approximately the diameter of a 
bead particle) in order for a chemiluminescent signal to be 
generated. Donor beads contain a photosensitizing agent 
(phthalocyanine) that, when irradiated at 680 nm, excites 
ambient oxygen to a singlet state. Excitation of each Donor 
beads generates approximately 60,000 oxygen singlets per 
second [8], resulting in a highly amplified response upon 
interaction with Acceptor beads.  
  In all AlphaScreen assays, the Acceptor beads contain   
three chemical dyes; thioxene, anthracene and rubrene   
(hence the designation, ‘TAR’ beads). Thioxene reacts ini- 
tially with singlet oxygen to produce light energy, which is  
subsequently transferred to anthracene and thence to rubrene.  
The final compound in the cascade, rubrene, emits light at  
wavelengths of 520-620 nm. Since this process occurs   
against a very dark background, highly sensitive assays can  AlphaScreen Technology in HTS  Current Chemical Genomics, 2008, Volume 1    3 
be developed. Moreover, the bead particles are often present  
in assays in low concentrations. Consequently, non specific  
close proximity interactions of Donor and Acceptor particles  
is rare and again the background is low (Fig. 1). Since the  
lifetime of the singlet oxygen reactive species in aqueous   
solutions is very short (approx. 4 ms), donor and acceptor  
beads need to be bound (frequently via an immunological  
complex) to one another in order to generate a signal. Those  
unbound beads experience extremely low singlet oxygen   
concentrations, and thus contribute minimally to the back-
ground signal. Recently, Acceptor beads have been modified  
to contain Europium, and commercialized as AlphaLISA   
assays. In AlphaScreen assays using TAR beads the conver-
sion of dioxetane to diketone (due to the reaction of thioxene  
with singlet oxygen) can be rate limiting. By contrast, Al- 
phaLISA beads, containing Europium, provide an emission  
that is very highly intense and spectrally defined (615 nm),  
in comparison to AlphaScreen assays (520 - 620nm).  
  In both AlphaScreen and AlphaLISA assays, the bead 
surface are coated with latex-based hydrogels containing 
reactive aldehydes. This coating both reduces non specific 
binding but additionally provides a functionalized surface to 
which a variety of different ligand or receptor binding part-
ners may be affixed. Collectively, these surface properties 
allow quantitation of a wide range of enzymes, protein-
protein interactions, as well as DNA and RNA hybridization. 
In contrast to the short distances required for resonance en-
ergy transfer (RET) approaches, AlphaScreen Do-
nor/Acceptor pairs can be separated by as far as 200 nm for 
energy to transfer efficiently. The size of the separation dis-
tance (which is relatively large by comparison to FRET tech-
niques) allows greater flexibility in the choice of analyte (up 
to and including large proteins and even phage particles) that 
can be quantitated. 
  As mentioned above, AlphaScreen was developed from 
LOCI technology; a bead based assay technology developed 
in the mid 1990’s by Ullman and colleagues [6-7] at Syva 
Diagnostics (later Dade Behring). It was designed to meas-
ure clinically important analytes (including cyclosporine, 
digoxin, estradiol, folate, theophylline or TSH) in plasma or 
serum and later, tissue nucleic acids [9] (Table 1). A major 
advantage of the method was that, even though there were no 
fluid separation steps in the assay protocol, interference by 
blood constituents was markedly reduced. Currently, several 
Svya/Dade Behring LOCI assays continue to be widely used 
in the in vitro diagnostics industry. In 1999, PerkinElmer 
acquired the exclusive rights to develop LOCI technology 
for use in research and drug discovery applications. Cur-
rently commercialized from this company under the name, 
AlphaScreen, and now AlphaLISA [1], the technology has 
been used to measure several signal transduction molecules 
including cyclic AMP [10-11] and inositol [1, 4, 5] trisphos-
phate [12], as well as protein kinases [4, 5, 11, 13] and pro-
teases [8, 14]. It has also been used in proteomics [15] and 
genomics studies in addition to screening at nuclear hormone 
receptors [3, 16-18], transcription factors [19], and single 
nucleotide polymorphisms (SNPs) [2, 20, 21]. 
  There is, therefore, a significant literature now available 
on the use of the technique in many laboratories. This paper 
assesses the current status of AlphaScreen and AlphaLISA in 
both basic drug discovery research and HTS. 
ALPHASCREEN ASSAYS FOR HTS 
Second Messenger Accumulation Assays 
  Almost all HTS assay protocols require sequential addi-
tion of reagents. Consequently, sandwich competition im-
munoassays are frequently used. In the case of AlphaScreen, 
 
 
 
 
 
 
 
 
 
 
Fig. (1). AlphaScreen/AlphaLISA Assay Principle 
AlphaScreen/AlphaLISA assays are bead based proximity assays, based upon an oxygen channeling technology. When the Donor (blue 
bead), which contains phthalocyanine, is laser excited (at 680 nm) ambient oxygen is converted to singlet oxygen. This is a highly amplified 
reaction since approx. 60,000 singlet oxygen molecules can be generated and travel at least 200 nm in aqueous solution before decay. Conse-
quently, if the Donor and Acceptor (gold beads) beads are within that proximity, energy transfer occurs. Singlet oxygen molecules react with 
chemicals in the Acceptor beads to produce a luminescent response. If the Acceptor bead contains Europium, as in the AlphaLISA assay, an 
intense luminescence is emitted at a wavelength of 615 nm.  
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assay times are minimized by using, as a first reagent addi-
tion, antibody-labeled beads as well as a second antibody 
labeled with biotin. Both reagents have good stability and 
can be stored together with minimal nonspecific binding 
prior to use. The second reagent comprises streptavidin-
labeled beads, often added in relatively high concentrations. 
Attaching the second antibody to this bead, as opposed to the 
inclusion a second antibody with the first reagent, leads to 
slower rate of binding in the second step. Consequently, in 
most assay formats, AlphaScreen employs Donor beads 
coated with streptavidin that bind biotinylated proteins, pep-
tides or small molecules. In the majority of assays, Acceptor 
beads are coupled to their cognate binding partners opti-
mized to detect the analyte under investigation.  
  AlphaScreen has been used to develop assays to measure 
cAMP accumulation, particularly for high throughput cell-
based GPCR screening [10, 11]. AlphaScreen has also been 
developed to measure other cyclic nucleotides, such as 
cGMP, using an analogous format. AlphaScreen cAMP as-
say employs Donor beads coated with streptavidin in order 
to bind biotinylated cAMP. The acceptor beads are coated 
with anti-cAMP antibodies. Bound biotinylated cAMP inter-
acts with anti-cAMP antibodies, bringing Donor and Accep-
tor beads into close proximity. Singlet oxygen then transfers, 
resulting in a chemiluminescent signal (Fig. 2). Addition of 
the cell lysate containing free cAMP competes with biotiny-
lated cAMP for the antibody, reducing the signal in a con-
centration-dependent fashion. This assay is usually under-
taken using the crude cell lysate following activation of the 
GPCR. 
  In modern HTS laboratories, numerous homogeneous 
assays are now available for the measurement of cAMP ac-
cumulation in response to liganded GPCR activation includ-
ing Time Resolved Fluorescent Energy Transfer (TR-FRET), 
Fluorescent Polarization (FP), Enzyme Fragment Comple-
mentation (EFC) and Electrochemical Luminescence (ECL) 
techniques. Most provide an order of magnitude in sensitiv-
ity in detection such that about 10 femtomolar cAMP per 
well can be measured. However, it must be noted that 
AlphaScreen and ECL are chemiluminescent technologies 
that, whilst robust and cheap, require a specific detection 
instruments.  
  Surprisingly few studies have been reported a direct 
comparison all of these methods. However, Elster et al. [23] 
have recently compared the pharmacology of 1-adrenergic 
receptor ligands, measured by -arrestin translocation assays 
via bioluminescence resonance energy transfer (BRET), with 
that obtained using cAMP responses quantified using Al-
phaScreen. It was found that both techniques detected full 
agonism and antagonism, yet only the AlphaScreen assay 
was sensitive enough to detect inverse agonism. However, it 
is probable that the disparity was due less to the assay meth-
ods evaluated, but is more to a greater ‘receptor reserve’ 
associated with the “downstream” response of cAMP accu-
mulation, in comparison to -arrestin translocation. 
AlphaScreen Assays for protein kinases 
  Kinases serve to catalyze the transfer of terminal phos-
phate groups from ATP to target substrates [24-27]. They 
comprise two major families - those that catalyze phosphory-
lation of tyrosine residues and those that phosphorylate ei-
ther serine or threonine residues. AlphaScreen assays have 
now been developed to detect the function of both families 
[4, 5, 13, 28]. In the case of tyrosine kinases, AlphaScreen 
assays utilize antibodies selective for phosphorylated tyro-
sine residues. These are directly conjugated to Acceptor 
beads and biotinylated peptides, acting as kinase substrates, 
were conjugated to Donor beads. Binding of biotinylated 
phosphorylated substrates and the phosphoselective antibod-
ies coordinates the Donor and Acceptor beads into close 
proximity and generates an assay signal (Fig. 2).  
  In general, serine/threonine kinases exhibit higher speci-
ficity for substrates in comparison to substrates for tyrosine 
kinases. Consequently, very selective antibodies are required 
to detect serine/threonine kinase function. To this point, Al-
Table 1.  Timeline for Development of AlphaScreen Technology 
1994 - LOCI developed by Syva/Dade Behring to measure clinical analytes in human fluids [6,7] 
1999 - LOCI commercialized for nucleic acid detection in miniaturized formats [9] 
1999 - LOCI technology licensed by PerkinElmer for drug discovery applications [1] 
2001 - AlphaScreen HTS cAMP assay [10,11] 
2001 - AlphaScreen assay for single nucleotide polymorphism (SNP) detection [2, 20, 21] 
2002 - AlphaScreen Nuclear Receptor Assay 3, [16, 18] 
2003 - AlphaScreen Ins P3 assay [12] 
2003 - AlphaScreen Protease assay [8, 14] 
2003 - AlphaScreen protein kinase assays [11, 13] 
2005 - AlphaScreen Transcription factor assays [19] 
2005 - AlphaScreen Ubiquitin ligase assay [33] 
2006 - Cell based kinase assays using Surefire (AlphaScreen) technology [5] 
2006 - Homogeneous ELISA (AlphaLISA) assays [15, 37] AlphaScreen Technology in HTS  Current Chemical Genomics, 2008, Volume 1    5 
phaScreen assays have now been developed using antibodies 
that specifically detect the phosphorylated substrate. Here, 
Acceptor beads are usually conjugated to protein A in order 
to bind mouse or rabbit derived antibodies. Both phosphory-
lated biotinylated peptides as well as phosphorylated GST-
fusion protein substrates can be used to bind to streptavidin 
or glutathione (GSH) coated Donor beads, respectively. In 
this format either peptides or proteins kinase substrates, once 
phosphorylated, bind to the anti-phosphoprotein antibodies, 
thus generating an assay signal (Fig. 2). 
  In a similar fashion to GPCRs, many homogeneous as-
says are now available for screening at kinases, including 
TR-FRET, FP, EFC, and ECL. All require selective antibod-
ies to detect the phosphorylated peptide. In the case of ser-
ine/threonine kinases, this requirement restricts the type of 
assay that can be developed. In an attempt to overcome these 
limitations, TR-FRET, EFC and FP approaches have been 
adapted to use Lewis metals to coordinate the substrate 
phospho group, as a surrogate of a phospho specific anti-
body. Consequently, a similar approach using Lewis metals 
has also been reported using AlphaScreen [29, 30]. Here, the 
phosphorylated kinase substrate can be either biotinylated or 
generated as a GST fusion protein - which is captured by 
either streptavidin coated or Glutathione coated Donor 
beads, respectively (Fig. 2). The acceptor beads are then 
coated with Lewis metal chelates that act to coordinate sub-
strate phosphate groups. Once phosphorylated GST labeled 
kinase substrates bind to the Lewis metal chelate, they are 
then captured by GSH coated Donor beads forming a prox-
imity interaction. Although none of the ‘antibody free meth-
ods’ discriminate between multiple phosphorylation events 
on the same substrate, a major advantage of the AlphaScreen 
approach, in comparison to TR-FRET, is that both protein or 
peptide substrates can be used. 
  A second assay format often utilized to measure ser-
ine/threonine kinase activity employs a “sandwich” immu-
noassay approach (see Fig. 3). In this format, an antibody 
pair is used to detect phosphorylated substrates, in a manner 
fashion to a classical ELISAs. One antibody is used to detect 
the form of kinase substrate independent of its phosphoryla-
tion state and a distinct, second antibody is used that is spe-
cific to the phosphorylated state of the substrate. One of the 
antibodies is biotinylated and then captured to the bead. 
Streptavidin coats the Donor beads while the Acceptor beads 
are labeled with the second antibody in a similar manner to 
that employed in a typical AlphaScreen IgG assay. This for-
mat has the major advantage that it does not require substrate 
labeling yet provides greater sensitivity than many ELISA 
based methods. 
  The assays discussed above measure kinase function as a 
means to measure the potency of a putative enzyme inhibi-
tor. One problem with the approach is that the kinase under 
investigation needs to exhibit significant activity (in terms of 
substrate phosphorylation) to generate a detectable assay 
signal. However, numerous kinases of clinical importance 
are expressed with only low activity. A recent development 
of AlphaScreen technology therefore is to directly measure 
the potency of the kinase inhibitor via its binding constant, 
using peptide substrates that interact at the kinase active site. 
Indeed, such peptides may be used as probes that can iden-
tify selective inhibitors acting at the substrate binding site. 
This concept, described in Guenet et al. [5] for Jun kinase 3 
(JNK 3), involves coupling, via a His tag, of the kinase to a 
nickel ion coated Acceptor bead, together with the conjuga-
tion of either the kinase substrate (e.g. cJun) or a peptide 
inhibitor as a GST fusion protein to the Donor beads (previ-
ously coated with an anti-GST antibody). When either c Jun, 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Comparative protocols of ELISA vs. AlphaLISA assays 
In these schematic protocols, panel on the left illustrates the multiple wash and separation steps required in a typical ELISA experiment. By 
contrast, the use of the AlphaLISA allows experiments to be conducted using simple mix and read protocols.  
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or a JNK inhibitor peptide, binds to JNK3, a luminescent 
response is detected via a proximity assay.  
  In most inhibitor programs, most compounds are directed 
against the ATP binding domain - a site that is highly con-
served across kinases. Consequently, attainment of high 
kinase specificity may be problematic since ATP-site selec-
tive compounds possess a degree of cross reactivity to other 
kinases. By contrast, small molecules that selectively inhibit 
unique orthogonal substrate binding sites are thought to have 
higher selectivity. Consequently, kinase binding assays are 
now been emerging as HTS assays and have been reported 
using both EFC [31] or TR-FRET techniques, in addition to 
the AlphaScreen approach discussed above. 
  In the assays described above, most employ cell-free 
(“biochemical”) formats that mandate the use of highly puri-
fied kinases and kinase domains. However, there is now a 
significant move in screening programs towards assay tech-
nologies capable of studying kinase function in the cell - 
particularly those use homogeneous protocols adaptable to 
high throughput instrumentation. In this regard, AlphaScreen 
assays have a unique advantage in that they can be devel-
oped to measure kinase phosphorylation of endogenous sub-
strates, including other kinases in the signaling pathway, in 
the intact cell. Osmond et al. [32] described an AlphaScreen 
assay to measure the phosphorylation of ERK1/2  following 
GPCR activation. This involves antibodies that selectively 
detect phosphorylated ERK1/2 (coordinated by protein A Ac-
ceptor beads) and biotinylated antibodies detecting ERK1/2 
independent of the phosphorylation state (captured by strep-
tavidin donor beads). This approach (commercialized under 
the term Surefire) can be employed for both GPCR screening 
as well as for growth factor receptors, such as TNF recep-
tors (Fig. 3). Recently, analogous assays have now been de-
veloped to measure phosphorylation other kinases, including 
p38 MAPK, JNK3, MEK, AKT and p70.  
AlphaScreen Assays for proteases 
  AlphaScreen assays have been reported to measure activ-
ity of the protease, ADAM [8]. This enzyme acts to cleave 
the protein, aggrecan, which is a critical step for cartilage 
formation and for which disregulation is involved in the eti-
ology of arthritic joint disease. Peppard et al. [8] developed a 
protease assay by coating both Donor and Acceptor beads 
with antibodies targeting different epitopes of aggrecan, thus 
allowing the protein to create a bridge between the beads. A 
luminescent response was then detected only when full 
length protein substrates were present. In the presence of the 
protease, ADAM, the Aggrecan Bridge is hydrolyzed and the 
luminescent signal reduced. The assay was used to screen a 
library of small molecules in an HTS format. Although many 
HTS technologies are now available to measure protease 
activity, several specific advantages are uniquely conferred 
by an AlphaScreen approach [8], including the ability to use 
much larger substrates than can be utilized in traditional 
FRET-based assays. Moreover, Peppard et al. [8] used es-
sentially four antibodies and the large molecular weight ag-
grecan to bridge the Donor/Acceptor bead complex. Using 
full length protein substrates has the advantage in that sev-
eral proteases possess multiple cleavage sites. Employing 
peptide substrates that encompass only single cleavage sites 
will miss critical protease function detectable only with the 
use of large protein substrates.  
Ubiquitin Ligase AlphaScreen Assays 
  Many cellular proteins undergo ubiquitination; a post-
translational modification that “targets” proteins for degrada-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Surefire assay principle 
The AlphaScreen platform can be used to detect analytes in a crude cell lysate using protocols developed into the Surefire format. Here, the 
levels of a phosphorylated protein (such as phosphoERK1/2 can be quantified using the approach, by use of specific antibodies to the phos-
phoprotein, without wash and separation steps as in a typical ELISA assay. 
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tion in the proteosome. This modification is mediated by the 
E3 ligase family and which is therefore essential for normal 
protein turnover. Consequently, disregulation of E3 ligase 
activity causes pathologies such as Alzheimer’s and Parkin-
son’s disease, several cancers, and inflammatory diseases. 
Despite the importance of ubiquitin ligases as therapeutic 
targets, most current HTS approaches at these targets are low 
in throughput and primarily employ immunoblotting tech-
niques. Kus et al. [33] have developed an E3 ligase assay 
using AlphaScreen technology to identify novel substrates 
that may undergo ubiquitination. This group screened the 
yeast E3 ligase, Rsp5, against a large number of GST tagged 
protein substrates to identify optimal Rsp5 substrates. The 
assay utilizes the transfer of biotinylated ubiquitin to target 
substrates by Rsp5, resulting in the production of biotiny-
lated and ubiquitinated GST tagged proteins. The biotin tag 
present on the ubiquitinated GST fusion protein allowed its 
simultaneous capture by streptavidin Donor and anti-GST 
/Acceptor beads resulting in signal generation. Kus et al. 
[33] identified several substrates for Rsp5 including many 
unknowns. Subsequently, the ubiquitination of these sub-
strates was confirmed in orthogonal assays using gel electro-
phoresis and cellular toxicity assays.  
Protein-Protein Interaction Assays Using AlphaScreen 
  Many cellular reactions involve complex protein-protein 
interactions, ranging from ligand/ GPCR binding, G protein 
coupling, interaction of kinases with cognate substrates as 
well as the interaction of transcription factors with nuclear 
co-activators and co-repressors. Partly due to this cellular 
complexity, few HTS technologies have been developed that 
measure protein-protein interactions that can be used to iden-
tify either small molecule inhibitors or novel interacting 
partners. In this respect AlphaScreen technology has 
emerged as a useful assay platform to measure protein: pro-
tein interactions, as will be discussed below. 
Growth Factor Receptor Binding 
  Tumor necrosis factor (TNF) receptors are implicated in 
the etiology of many inflammatory and immunological dis-
orders. Wilson et al. [17] developed an AlphaScreen assay to 
measure ligand binding to a member of the TNF receptor 
super-family, OX40 (CD 134). A fusion protein was gener-
ated in which OX40 was coupled to a domain of human IgG, 
allowing OX40 to bind to Acceptor beads coated with pro-
tein A. An OX40 ligand (OX40L-CD8) tagged with biotin 
which was coordinated by streptavidin coated Donor beads. 
The binding of OX40L to OX40 bridged of Acceptor/Donor 
beads and therefore generated a signal. Therefore, OX40 
ligand binding could directly measured in a HTS format and 
subsequently, several peptides and small molecule were 
identified that inhibited OX40L binding.  
Transcription Factors 
  AlphaScreen technology has also been adapted to meas-
ure the interaction of various transcription factors with nu-
clear binding sites. Rouleau et al. [3] have reported an Al-
phaScreen assay to measure interactions between estradiol-
bound estrogen receptors (ER) and the steroid receptor co-
activator 1 (SRC-1). ER was coordinated to Acceptor beads 
coated with anti-ER antibodies and a peptide fragment (de-
rived from SRC-1 sequences) was biotinylated and coupled 
to streptavidin coated donor beads. ER agonists induced the 
interaction of ER with SRC-1 and resulted in an assay signal. 
The assay exhibited pharmacological characteristics similar 
to that observed using other technologies. An equivalent 
assay for the retinoic acid receptor was also developed and 
again exhibited appropriate pharmacological specificity. Col-
lectively, these studies indicated that AlphaScreen technol-
ogy could be used to identify novel ligands and inhibitors 
acting at nuclear receptor binding sites in high throughput 
assay protocols.  
Viral Protein Binding 
  An important molecular interaction with regard to infec-
tious disease and oncology is the mechanism by which viral 
proteins induce cell transformation and proliferation. For 
example, Human papilloma virus (HPV) is a major cause of 
cervical cancer. HPV induces cell transformation in part by 
inhibiting the activity of p53, and by blocking transformed 
cells from undergoing apoptosis. These effects result from an 
interaction of HPV protein E6 with the ubiquitin ligase, 
E6AP. Consequently, small molecules that inhibit the bind-
ing of E6 to E6AP may attenuate the ability of HPV to cause 
cervical cancers. Sehr et al. [34] reported an AlphaScreen 
assay to measure E6 binding to a peptide fragment of E6AP 
and used the assay to detect inhibitors of the interaction. 
Here an E6-GST fusion protein was bound to Acceptor 
beads coated with either anti-GST antibodies or GSH. A 
biotinylated peptide fragment of E6AP, known to be a site of 
interaction of E6 was synthesized and bound to Streptavidin 
coated Donor beads. Using this approach, Sehr et al. [34] 
screened approximately 3000 small molecules and identified 
several leads that were validated in subsequent screens. 
ALPHALISA 
  Currently, most biomarker analysis requires high capac-
ity detection of analytes as markers of biomolecular reac-
tions. The scale of high throughput analysis requires detec-
tion instrumentation and assay platforms easily adapted to 
automated systems. A standard approach used for many 
years in biomarker analysis is ELISA technology. Although 
conventional ELISAs readily detect analytes in the low pi-
comolar (pM) range, they have several limitations that re-
strict their use in high throughput protocols (Table 2). Spe-
cifically, ELISAs require multiple washing steps to remove 
non-specifically adsorbed reactants (Fig. 2). These are both 
time consuming and require complex instrument program-
ming that serve to increase assay costs and decrease preci-
sion. Although ELISAs handle relatively low sample vol-
umes adequately, larger volumes are usually needed due to 
limitations in assay sensitivity. This is restrictive in screens 
where the target analyte is present only in low concentra-
tions. Furthermore, many ELISAs often exhibit approxi-
mately two orders of magnitude in dynamic range. Conse-
quently, the sample has to be diluted several times to bring 
analytes levels within the range of ELISA detection. A com-
parison of AlphaScreen /AlphaLISA platforms with other 
assay formats are shown in Table 3. 
  The AlphaLISA platform is an evolution of the AlphaS-
creen technology designed to meet requirements for high 
throughput assays for biomarker detection. AlphaLISA re-
sembles AlphaScreen, except that the beads contain Euro-
pium as the Acceptor fluor. Europium emission is more in-8    Current Chemical Genomics, 2008, Volume 1  Eglen et al. 
tense and better defined spectrally (615 nm) than observed in 
AlphaScreen assays (520-620nm). Consequently, the emis-
sion wavelength is less prone to matrix interferences from 
compounds such as hemoglobin or transferrin. AlphaLISA 
assays also require small sample volumes (5 μl) yet they 
have over a 100-fold greater analytical range than ELISA. 
Since AlphaLISA can employ the same antibody pairs assays 
using this approach exhibits equivalent selectivity to ELISAs 
but are more sensitive due to its highly amplified nature. 
  Poulsen and Jensen [15] have recently reported direct 
comparisons of AlphaLISA and ELISA assays to measure 
human insulin in plasma samples. The assay sensitivity was 
shown to be in the sub-picomolar range with a ten thousand 
fold dynamic range of detection. The assay also had excel-
lent intra- and inter-assay precision and was unaffected by 
plasma and serum matrices. The samples were then simulta-
neously analyzed using the AlphaLISA and a standard 
ELISA method using the same antibody pairs and a good 
correlation between the two was seen. Furthermore, AlphaL-
ISA detected 15-fold lower levels of analyte than ELISA, 
while using one fifth the sample volume. It also had over 
100-fold greater assay range with similar precision levels. 
The authors thus concluded that AlphaLISA platform pro-
vided a viable alternative to ELISA and being homogenous 
was more amenable to automated fluid dispensing systems. 
  Several other technologies, besides AlphaLISA, have 
also been developed as ELISA alternatives. Two technolo-
gies to note are the homogenous fluorometric microvolume 
Table 2.  Comparison of AlphaLISA with ELISA Techniques 
  ELISA AlphaLISA 
Selectivity High  High 
Sensitivity  Sensitive (pM range)  Sensitive (sub-pM) 
Assay Format Heterogeneous  Homogenous 
Antibody req.  Requires matched antibody pairs  Used with antibody pairs 
Assay vol. large  (25-50  μl) small  (> 5 μl) 
Dynamic range  limited (~2 orders of mag.)  large (~4 orders of mag.) 
Instrumentation  any luminescent reader  requires high energy laser 
 
Table 3.  Comparison of AlphaScreen/AlphaLISA Platforms with LANCE and DELFIA 
 AlphaScreen/AlphaLISA™  LANCE  DELFIA 
Detection  Luminescence 
Proximity 
TR-FRET TRF 
Homogenous  Yes Yes  No 
Throughput  High Ultra-High  Medium 
Automation  **** ****  * 
Sensitivity  **** ***  **** 
Dynamic range  2.5 - 5 logs  2 - 3 logs  2.5 - 5 logs 
Microplate formats  96, 384, 1536  96, 384, 1536  96, 384 
Multiplexing  No  No  up to 4-plex 
Substrate sizes  Small molecules 
to whole cells 
Small molecules 
to peptides 
Small molecules to proteins, 
Use of low affinity  
antibodies 
Yes Limited;  impact 
on data quality 
No 
Use of polyclonal  
antibodies 
Yes Limited;  only 
special affinity 
purified Abs 
Yes 
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assay technology (FMAT) [35] and ECL [36]. FMAT can be 
formatted such that biotinylated antigen interacts with strep-
tavidin coated beads. An AlexaFluor-647 tagged antibody 
binds to antigen and a luminescent signal is emitted from 
aggregated beads. Specific signal is then discerned from 
background using laser-scanning microscopy. In an ECL 
assay, biotinylated antigen is bound to Streptavidin coated 
electroplates and binding of ruthenium-labeled anti-mouse 
antibodies in close proximity to an electroplate results in a 
chemiluminescent signal. Like AlphaLISA, FMAT and ECL 
technologies are highly sensitive, do not require extensive 
washing and can be formatted for HTS. Beasley et al. [37] 
have recently preliminary data that compared FMAT, ECL 
and AlphaLISA methods to detect common biomarkers. 
Here, AlphaLISA exhibited higher sensitivity and required 
lower sample volumes than the other assays. They also indi-
cated that ECL and FMAT techniques involved the use of 
specialized detection instrumentation (laser scanning micros-
copy for FMAT) and equipment (electrochemical plates for 
ECL) which limited their flexibility yet increased assay cost. 
ECL was also limited by the high costs of the consumable 
electrochemical plates required.  
SUMMARY 
  As with any assay technology there are advantages and 
limitations and this is also extends to AlphaScreen/Alpha-
LISA assays. The main disadvantage of AlphaScreen tech-
nology is that it is sensitive to intense light or long exposure 
to ambient light. Although this issue was reported in the 
original publications describing LOCI technology, the prob-
lem is now easily overcome by simple assay adjustments. In 
addition, singlet oxygen can be sequestered by compounds in 
screening libraries that can scavenge radical oxygen. Donor 
bead photo bleaching can be a limitation in that the system is 
effectively limited to a single read. Although AlphaScreen 
has greater flexibility than technologies such as ECL and 
FMAT, all three require a high-energy laser excitation 
source. Consequently, Alphascreen is not adaptable to all 
readers and in this respect is more limited than other lumi-
nescent technologies. 
  The main advantage of the technology is that it is appli-
cable to a very broad range of analytes, some of which have 
been addressed in this review. All the assays are homogene-
ous, rapid, and robust yet appear to be more sensitive than 
previously reported immunoassay methods. Furthermore, 
AlphaScreen assays do not require insertion of large fluores-
cent epitope tags that may sterically hinder bio molecular 
interactions. AlphaScreen and notably AlphaLISA can be 
employed to measure enzyme activity in crude biological 
fluid extracts such as cell lysates, serum and plasma and a 
variety of cellular/body fluid matrices that do not easily af-
fect the assay readout.  
CONCLUSION 
  Both AlphaScreen and AlphaLISA assays can be used to 
measure a diverse range of molecular interactions of interest 
throughout drug discovery. The homogenous nature of the 
technique allows it to be an important tool in high through-
put screening of new small molecules and, most recently, of 
novel protein therapeutics. For example, it has been used for 
hybridoma-screening for thousands of clones that express 
antibodies for therapeutic development. Such screening 
presently involves use of ELISAs which, as noted above, are 
less adaptable for high capacity screening and potentially 
more costly.  
  The ability of AlphaScreen to measure post-translational 
protein modification offers novel uses in screening. Al-
though measurement of second messenger accumulation has 
been a major application of AlphaScreen technologies, these 
processes can now also be measured by alternative technolo-
gies. However, other cell signaling events such as phos-
phorylation, proteolysis, ubiquitination, sumoylation and 
glycosylation, remain difficult to measure. AlphaScreen 
technology has now been used to successfully screen against 
these processes. Consequently, novel small molecules or 
biotherapeutics may be identified to treat disorders such as 
Alzheimer’s, Parkinson’s and Huntington’s disease, as well 
as oncology and various immunological disorders. 
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